|
1
|
Glorioso JM, Mao SA, Rodysill B, Mounajjed T, Kremers WK, Elgilani F, Hickey RD, Haugaa H, Rose CF, Amiot B, Nyberg SL. Reply to: "Pivotal preclinical trial of the spheroid reservoir bioartificial liver". J Hepatol 2015; 63:1052-3. [PMID: 26143442 DOI: 10.1016/j.jhep.2015.06.024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/24/2015] [Accepted: 06/25/2015] [Indexed: 12/04/2022]
Affiliation(s)
| | - Shennen A Mao
- Department of Surgery, Mayo Clinic, Rochester, MN, USA
| | | | - Taufic Mounajjed
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - Walter K Kremers
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA
| | - Faysal Elgilani
- William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA
| | - Raymond D Hickey
- William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA
| | - Hakon Haugaa
- Department of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Norway
| | | | - Bruce Amiot
- Brami Biomedical, Inc., Minneapolis, MN, USA
| | - Scott L Nyberg
- Department of Surgery, Mayo Clinic, Rochester, MN, USA; William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA.
| |
Collapse
|
|
2
|
Glorioso JM, Mao SA, Rodysill B, Mounajjed T, Kremers WK, Elgilani F, Hickey RD, Haugaa H, Rose CF, Amiot B, Nyberg SL. Pivotal preclinical trial of the spheroid reservoir bioartificial liver. J Hepatol 2015; 63:388-98. [PMID: 25817557 PMCID: PMC4508211 DOI: 10.1016/j.jhep.2015.03.021] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Revised: 03/13/2015] [Accepted: 03/19/2015] [Indexed: 02/08/2023]
Abstract
BACKGROUND & AIMS The neuroprotective effect of the spheroid reservoir bioartificial liver (SRBAL) was evaluated in a porcine model of drug-overdose acute liver failure (ALF). METHODS Healthy pigs were randomized into three groups (standard therapy (ST) alone, ST+No-cell device, ST+SRBAL device) before placement of an implantable intracranial pressure (ICP) monitor and a tunneled central venous catheter. One week later, pigs received bolus infusion of the hepatotoxin D-galactosamine and were followed for up to 90h. RESULTS At 48h, all animals had developed encephalopathy and biochemical changes confirming ALF; extracorporeal treatment was initiated and pigs were observed up to 90h after drug infusion. Pigs treated with the SRBAL, loaded with porcine hepatocyte spheroids, had improved survival (83%, n=6) compared to ST alone (0%, n=6, p=0.003) and No-cell device therapy (17%, n=6, p=0.02). Ammonia detoxification, peak levels of serum ammonia and peak ICP, and pig survival were influenced by hepatocyte cell dose, membrane pore size and duration of SRBAL treatment. Hepatocyte spheroids remained highly functional with no decline in mean oxygen consumption from initiation to completion of treatment. CONCLUSIONS The SRBAL improved survival in an allogeneic model of drug-overdose ALF. Survival correlated with ammonia detoxification and ICP lowering indicating that hepatocyte spheroids prevented the cerebral manifestations of ALF (brain swelling, herniation, death). Further investigation of SRBAL therapy in a clinical setting is warranted.
Collapse
Affiliation(s)
| | - S. A. Mao
- Department of Surgery, Mayo Clinic, Rochester, MN, USA
| | - B. Rodysill
- Department of Surgery, Mayo Clinic, Rochester, MN, USA
| | - T. Mounajjed
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - W. K. Kremers
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA,William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA
| | - F. Elgilani
- William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA
| | - R. D. Hickey
- William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA,Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA
| | - H. Haugaa
- Department of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway,Institute of Clinical Medicine, University of Oslo
| | - C. F. Rose
- Hepato-Neuro Laboratory, CRCHUM, Universite de Montreal, Quebec, Canada
| | - B. Amiot
- Brami Biomedical, Inc. Minneapolis, MN, USA
| | - S. L. Nyberg
- Department of Surgery, Mayo Clinic, Rochester, MN, USA,William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA,Corresponding address: Scott L. Nyberg, MD, PhD, William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, 200 First Street, Rochester, MN 55905
| |
Collapse
|
|
3
|
Weeks CA, Newman K, Turner PA, Rodysill B, Hickey RD, Nyberg SL, Janorkar AV. Suspension culture of hepatocyte‐derived reporter cells in presence of albumin to form stable three‐dimensional spheroids. Biotechnol Bioeng 2013; 110:2548-55. [DOI: 10.1002/bit.24899] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2013] [Revised: 02/25/2013] [Accepted: 02/28/2013] [Indexed: 01/26/2023]
Affiliation(s)
- C. Andrew Weeks
- Department of Biomedical Materials Science, School of DentistryUniversity of Mississippi Medical Center2500 North State StreetJacksonMississippi 39216
| | - Kristen Newman
- Department of Biomedical Materials Science, School of DentistryUniversity of Mississippi Medical Center2500 North State StreetJacksonMississippi 39216
| | - Paul A. Turner
- Department of Biomedical Materials Science, School of DentistryUniversity of Mississippi Medical Center2500 North State StreetJacksonMississippi 39216
| | - Brian Rodysill
- Division of Experimental SurgeryMayo Clinic College of MedicineRochesterMinnesota
| | - Raymond D. Hickey
- Division of Experimental SurgeryMayo Clinic College of MedicineRochesterMinnesota
| | - Scott L. Nyberg
- Division of Experimental SurgeryMayo Clinic College of MedicineRochesterMinnesota
| | - Amol V. Janorkar
- Department of Biomedical Materials Science, School of DentistryUniversity of Mississippi Medical Center2500 North State StreetJacksonMississippi 39216
| |
Collapse
|
|
4
|
Abstract
Cell therapies, which include bioartificial liver support and hepatocyte transplantation, have emerged as potential treatments for a variety of liver diseases. Acute liver failure, acute-on-chronic liver failure, and inherited metabolic liver diseases are examples of liver diseases that have been successfully treated with cell therapies at centers around the world. Cell therapies also have the potential to be widely applied to other liver diseases, including noninherited liver diseases and liver cancer, and to improve the success of liver transplantation. Here we briefly summarize current concepts of cell therapy for liver diseases.
Collapse
Affiliation(s)
- Yue Yu
- Department of Surgery, Division of Experimental Surgery, Mayo Clinic, Rochester, MN,Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, P.R. China
| | - James E. Fisher
- Department of Surgery, Division of Experimental Surgery, Mayo Clinic, Rochester, MN
| | - Joseph B. Lillegard
- Department of Surgery, Division of Experimental Surgery, Mayo Clinic, Rochester, MN
| | - Brian Rodysill
- Department of Surgery, Division of Experimental Surgery, Mayo Clinic, Rochester, MN
| | | | - Scott L. Nyberg
- Department of Surgery, Division of Experimental Surgery, Mayo Clinic, Rochester, MN
| |
Collapse
|